Kazia Therapeutics would like to share the media coverage of Professor Matt Dun of the University of Newcastle that was conducted around World Brain Tumour Day.
Professor Dun was interviewed across leading broadcast and print media about his research into Diffuse Intrinsic Pontine Glioma (DIPG), a rare but aggressive form of childhood brain cancer.
Professor Dun is one of Australia’s leading researchers in DIPG and began his research into the disease after his daughter – Josie, 3 – was sadly diagnosed with the disease last year.
His research is focused on testing new therapies in a bid to improve survival and Kazia’s brain cancer drug GDC-0084 is one of the therapies he has been working with.
Professor Dun was interviewed on Sunrise this week, speaking candidly about Josie and how he hopes his research will have a clinical benefit for her.
He was also interviewed in the Daily Telegraph on 8 June, and the story was widely syndicated across other News Corp papers. Of his experiments with GDC-0084, he notes that “we have tested 11 DIPG samples in the lab and they are all sensitive to the drug.”
Professor Dun was also featured on Channel 9 online where it mentions that he saw potential in GDC-0084 because the drug “targets one of the drivers of his daughter’s tumour”.
We look forward to updating you on our progress again soon. Thank you for your continued support.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.
TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.